JERAYGO

This brand name is authorized in Austria, Estonia, Ireland, Lithuania, UK.

Active ingredients

The drug JERAYGO contains one active pharmaceutical ingredient (API):

1	Aprocitentan UNII MZI81HV01P - APROCITENTAN
	Endothelin (ET)-1, via its receptors (ETA and ETB), mediates a variety of effects such as vasoconstriction, fibrosis, cell proliferation, and inflammation and is upregulated in hypertension. Aprocitentan is a dual ERA that inhibits the binding of ET-1 to ETA and ETB receptors and hence the effects mediated by these receptors.
	Read more about Aprocitentan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JERAYGO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C02KN01		C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KN Other antihypertensives
Discover more medicines within C02KN01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3083475, 3083486
LT	Valstybinė vaistų kontrolės tarnyba	1100108, 1100109, 1100110, 1100111